Akebia SVP CFO granted RSUs and options

Akebia Therapeutics reported an equity compensation grant to its senior executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer.

Rhea-AI Filing Summary

Akebia Therapeutics reported an equity compensation grant to its senior executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer. On January 30, 2026, he received 204,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 707,586 shares.

He was also granted stock options covering 320,000 shares of common stock at an exercise price of $1.41 per share, expiring on January 30, 2036. One third of the restricted stock units vest on each of the first three anniversaries of the grant date, while 25% of the options vest on the first anniversary and the remaining 75% vest in equal quarterly installments over the following three years, in each case contingent on continued service.

Insider Trade Summary

Grant/Award: 524,000 shares

Grant/Award 2 txns

Insider Ostrowski Erik

Role SVP, CFO, CBO & Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	320,000	$0.00	$0.00
Grant/Award	Common Stock	204,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 320,000 contracts (Direct); Common Stock — 707,586 shares (Direct)

Footnotes (2)

1. F1. The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
2. F2. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Akebia Therapeutics (AKBA) report for Erik Ostrowski?

Akebia Therapeutics reported new equity awards to Erik Ostrowski. On January 30, 2026, he received 204,000 restricted stock units of common stock and stock options for 320,000 shares, all granted under the 2023 Stock Incentive Plan, as amended.

How many Akebia Therapeutics (AKBA) shares does Erik Ostrowski hold after this Form 4?

After the transaction, Erik Ostrowski beneficially owns 707,586 common shares. This figure reflects the effect of the 204,000-share restricted stock unit grant reported on January 30, 2026, and is listed as directly owned common stock in the filing.

What are the terms of the stock option grant to Erik Ostrowski at Akebia Therapeutics (AKBA)?

Ostrowski received options on 320,000 Akebia shares at $1.41. The options expire on January 30, 2036. Vesting occurs over four years: 25% on the first anniversary of the grant, with the remaining 75% vesting in equal quarterly installments thereafter.

How do the restricted stock units granted to Erik Ostrowski at Akebia Therapeutics (AKBA) vest?

The 204,000 restricted stock units vest in three equal annual installments. One third vests on each of the first, second, and third anniversaries of the January 30, 2026 grant date, conditioned on Ostrowski’s continued service with Akebia on each vesting date.

Under which plan were Erik Ostrowski’s new Akebia Therapeutics (AKBA) awards granted?

The equity awards were granted under Akebia’s 2023 Stock Incentive Plan. Both the 204,000 restricted stock units and the 320,000 stock options are issued pursuant to the 2023 Stock Incentive Plan, as amended, as disclosed in the Form 4 footnotes.

Is the Akebia Therapeutics (AKBA) Form 4 for Erik Ostrowski a purchase or a grant?

The Form 4 reports equity grants, not open-market purchases. The transaction code is “A” for both the 204,000 restricted stock units and the 320,000 stock options, and the per-share price is listed as $0.00 for the grants themselves.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ostrowski Erik

(Last) (First) (Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST ST.

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CFO, CBO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		204,000(1)	A	$0.00	707,586	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.41	01/30/2026		A		320,000		(2)	01/30/2036	Common Stock	320,000	$0.00	320,000	D

Explanation of Responses:

1. The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

2. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Remarks:

	/s/ Carolyn M. Rucci, attorney-in-fact for Erik Ostrowski	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.